GLP-1 Agonists for Body Composition Research 2026
Clinical breakdown of GLP-1, GLP-1/GIP dual agonists, and GLP-1/GIP/glucagon triple agonists for metabolic body composition research. SURMOUNT, STEP, and TRIUMPH trial data.
The GLP-1 Agonist Body Composition Research Landscape
GLP-1 receptor agonists have transformed metabolic research over the past decade, evolving from single-receptor agents to sophisticated multi-receptor agonists that engage GIP, GLP-1, and glucagon pathways simultaneously. The research landscape has shifted decisively: where early GLP-1 compounds produced modest weight reductions of 5–8%, the current generation of dual and triple agonists is delivering 20–28% mean body weight reductions in Phase 3 clinical trials.
The mechanism explains the outcome. GLP-1 receptor agonism suppresses appetite and slows gastric emptying. Adding GIP receptor agonism enhances insulin secretion, reduces glucagon output, and — critically — amplifies the adipose tissue lipolysis signal. Adding glucagon receptor agonism directly stimulates hepatic fat oxidation and brown adipose tissue thermogenesis. Each additional receptor target compounds the body composition effect in a way that exceeds simple additive models. Retatrutide's 28.7% mean body weight reduction in Phase 3 is not incremental over semaglutide — it is categorical.
Dual Agonism Advantage: GIP + GLP-1
Tirzepatide's superiority over semaglutide in SURMOUNT-5 — 47% greater weight loss (20.2% vs 13.7%) — is explained by its simultaneous engagement of both GIP and GLP-1 receptors. GIP receptor agonism contributes mechanisms that GLP-1 agonism alone cannot replicate: enhanced postprandial insulin secretion with lower hypoglycemia risk, direct adipocyte signaling that promotes fat mobilization, and central nervous system effects that appear to reduce the nausea side-effect burden characteristic of pure GLP-1 agonists.
Triple agonism (retatrutide) adds glucagon receptor engagement to the GIP+GLP-1 framework, driving the highest body weight reductions observed in any pharmacological intervention to date.
Weight Loss & Body Recomposition Peptides
Body composition is the foundation of metabolic research. Three peptides dominate the current clinical landscape.
Retatrutide — The Triple Agonist
Retatrutide (CAS: 2381089-83-2) is Eli Lilly's first-in-class triple hormone receptor agonist, targeting GIP, GLP-1, and glucagon receptors simultaneously. The glucagon receptor component differentiates it from everything else — it directly stimulates hepatic fat oxidation, promotes thermogenesis via brown adipose tissue, and increases total energy expenditure by an estimated 2–3% beyond dual agonism.
| Dose | 24-Week Loss | 48-Week Loss |
|---|---|---|
| 1 mg | -7.2% | -8.7% |
| 4 mg | -12.9% | -17.1% |
| 8 mg | -17.3% | -22.8% |
| 12 mg | -17.5% | -24.2% |
| Placebo | -1.6% | -2.1% |
NEJM 2023, Phase 2 trial (n=338). TRIUMPH-4 Phase 3: -28.7% at 68 weeks.
Semaglutide — The Proven Standard
The most clinically validated weight loss peptide in existence. STEP 1: -14.9% weight loss (n=1,961, 68 wks). STEP 5: -15.2% sustained at 104 weeks. SELECT trial: 20% reduction in MACE in 17,604 participants.
Tirzepatide — The Dual Agonist
Dual GIP/GLP-1 agonist. SURMOUNT-5 head-to-head vs semaglutide: 47% greater weight loss (20.2% vs 13.7%). SURMOUNT-1 15 mg: -22.5%, with 57% losing 20%+ of body weight.
Browse Pre-Built Research Stacks
Starter, Dual Agonist, and Premium stacks — pre-selected combinations with products at every price point.
View All StacksSkin Quality Peptides
Naturally occurring copper-binding tripeptide. Plasma levels decline 60% between ages 20–60. Broad Institute data: modulates 4,000+ human genes, stimulates 47 DNA repair genes. 55.8% wrinkle volume reduction vs control.
GHK-Cu 50mg — $50.00Synthetic octapeptide that destabilizes the SNARE complex to attenuate — not eliminate — muscle contractions. 30% more effective than Argireline. Up to 63% wrinkle depth reduction. Preserves natural expressions.
SNAP-8 10mg — $45.00Synthetic tetrapeptide by Prof. Vladimir Khavinson. Activates telomerase through hTERT upregulation. Treated fibroblasts continued dividing past passage 44 vs passage 34 in controls. 6-year prospective cohort: 1.6–1.8-fold mortality reduction.
Epithalon 50mg — $139.99Recovery & Healing Peptides
BPC-157 — Body Protection Compound
Synthetic pentadecapeptide (15 amino acids) derived from human gastric juice. Over 36 published studies from Dr. Predrag Sikiric at the University of Zagreb. Heals via VEGFR2-dependent angiogenesis, FAK-paxillin cell migration, and dual nitric oxide pathways. No identified minimum toxic dose. The healing backbone of any comprehensive body composition research protocol.
BPC-157 10mg — $59.99TB-500 — The Systemic Healer
Synthetic thymosin beta-4 fragment. Principal regulator of monomeric actin availability — sequesters 40–50% of the total G-actin pool for rapid cytoskeletal remodeling during repair. Promotes cell migration, angiogenesis, and collagen deposition. Combined with BPC-157, forms the “Wolverine Stack” — complementary mechanisms targeting the full tissue repair cascade.
TB-500 10mg — $59.99Three Tiered Research Stacks
Based on available products, organized by budget and research goals.
- GLP-1 S 5mg (Semaglutide) — $79.99
- BPC-157 10mg — $59.99
- Bacteriostatic Water (x2) — $19.98
Most clinically validated weight loss (STEP 1–5, SELECT trial) + healing foundation.
- GLP-3 R 15mg (Retatrutide) — $189.99
- BPC-157 10mg — $59.99
- Bacteriostatic Water (x2) — $19.98
Phase 3 data: -28.7% weight loss. Triple receptor agonism with healing support. Free shipping.
- GLP-3 R 30mg (Retatrutide) — $349.99
- BPC-157 10mg — $59.99
- GHK-Cu 50mg — $50.00
- SNAP-8 10mg — $45.00
Body composition + recovery + skin rejuvenation + wrinkle reduction. Full metabolic and tissue research protocol.
Frequently Asked Questions
Tirzepatide engages both GIP and GLP-1 receptors, while semaglutide targets only GLP-1. GIP receptor agonism adds direct adipocyte signaling that promotes fat mobilization, enhanced postprandial insulin secretion, and CNS effects that appear to reduce GLP-1-associated nausea. SURMOUNT-5 confirmed 47% greater weight loss for tirzepatide vs semaglutide in a direct head-to-head trial (20.2% vs 13.7%).
Based on clinical trial data: Retatrutide leads at -28.7% (TRIUMPH-4 Phase 3), followed by Tirzepatide at -22.5% (SURMOUNT-1) and Semaglutide at -14.9% (STEP 1). Retatrutide is investigational; Tirzepatide and Semaglutide are FDA-approved.
GHK-Cu stimulates collagen and elastin synthesis in fibroblasts, modulates 4,000+ genes (Broad Institute data), stimulates 47 DNA repair genes, and promotes angiogenesis. Clinical research shows 55.8% wrinkle volume reduction vs control. Superior collagen production vs vitamin C and retinoic acid in 12-week trials.
Yes — BPC-157 and GLP-1 agonists target entirely different receptor systems. BPC-157 acts through VEGFR2 and nitric oxide pathways. GLP-1 agonists act through incretin receptors. No known pharmacological interaction. This combination forms the foundation of the Dual Agonist and Starter research stacks.
A starter research stack (Semaglutide + BPC-157) starts at ~$180. The Dual Agonist approach (Retatrutide + BPC-157) runs ~$310 with free shipping. A premium body composition + skin research stack adds GHK-Cu and SNAP-8 for ~$525.
Start Your Research Stack
Our trusted research supplier — research-grade Retatrutide, BPC-157, GHK-Cu, and more. Free shipping on orders over $200.